利肝隆联合异甘草酸镁治疗自身免疫性肝炎患者疗效及其对血清趋化因子水平的影响*

doi:10.3969/j.issn.1672-5069.2020.06.016

摘要/Abstract

摘要： 目的分析应用利肝隆联合异甘草酸镁治疗自身免疫性肝炎(AIH)患者的疗效及其对血清免疫球蛋白和趋化因子-8(CF-8)、CF-2和CF-9水平的影响。方法 2017年7月～2019年5月我院感染病科和消化内科收治的AIH患者122例,采用随机数字表法将其分对照组61例和观察组61例。在对照组,给予异甘草酸镁注射液治疗,观察组在对照组治疗的基础上给予利肝隆片治疗,两组均治疗3个月。采用ELISA法检测血清CF-8、CF-2和CF-9水平,采用免疫比浊法检测血清免疫球蛋白G(IgG)、IgM和IgA水平。结果在治疗结束时,观察组血清谷丙转氨酶(ALT)水平为(46.3±13.7)U/L,显著低于对照组【(82.5±14.2)U/L,P<0.05】和血清谷草转氨酶(AST)水平为(45.5±14.3)U/L,显著低于对照组【(66.7±16.8)U/L,P<0.05】;血清CF-8水平为(10.6±2.1)pg/mL,显著低于对照组【(15.8±3.3)pg/mL,P<0.05】,血清CF-2水平为(13.5±1.0)pg/mL,显著低于对照组【(19.0±1.3)pg/mL,P<0.05】,血清CF-9水平为(12.1±1.7)pg/mL,显著低于对照组【(15.8±1.4)pg/mL,P<0.05】;血清IgG水平为(1313.1±191.0)mg/L,显著低于对照组【(1816.4±311.6)mg/L,P<0.05】,血清IgM水平为(506.2±151.3)mg/L,显著低于对照组【(814.1±225.1)mg/L,P<0.05】,血清IgA水平为(509.1±128.6)mg/L,显著低于对照组【(749.7±231.9)mg/L,P<0.05】;在治疗过程中,观察组不良反应发生率为18.0%,与对照组的4.9%比,差异无统计学意义(P>0.05)。结论应用利肝隆联合异甘草酸镁治疗自身免疫性肝炎患者可抑制机体亢进的体液免疫反应,降低CF-8、CF-2和CF-9水平,显著改善患者肝功能,而不会增加用药后不良反应。

关键词: 自身免疫性肝炎, 利肝隆, 异甘草酸镁, 趋化因子-8, 治疗

Abstract: Objective The aim of this study was to analyze Liganlong, a herbal conpound, and magnesium isoglycyrrhizate combination how to mitigates liver injury in patients with autoimmune hepatitis (AIH). Methods 122 patients with AIH were admitted to Department of Infectious Diseases and Gastroenterology in our hospital between July 2017 and May 2019, and were divided into control group and observation group by computer-generated randomized numbers, with 61 cases in each. The patients in the control group were treated by intravenous infusion of magnesium isoglycyrrhizinate and those in the observation group were treated with Liganlong tablets orally at the basis of medicine in the control group. The regimen in both groups lasted for 3 months. Serum chemotactic factor (CF) and immunoglobulin (Ig) levels were detected. Results At the end of treatment, serum alanine aminotransferase (ALT) level in the observation group was (46.3±13.7) U/L, significantly lower than [(82.5±14.2) U/L, P<0.05] and serum aspartate aminotransferase (AST) level was (45.5±14.3) U/L, significantly lower than [(66.7±16.8) U/L, P<0.05] in the control group; serum CF-8 level was (10.6±2.1)pg/mL, significantly lower than 【(15.8±3.3)pg/mL, P<0.05】, serum CF-2 level was (13.5±1.0)pg/mL, significantly lower than 【(19.0±1.3)pg/mL, P<0.05】, and serum CF-9 level was (12.1±1.7)pg/mL, significantly lower than 【(15.8±1.4)pg/mL, P<0.05】; serum IgG level was (1313.1±191.0)mg/L, significantly lower than 【(1816.4±311.6)mg/L, P<0.05】, serum IgM level was (506.2±151.3)mg/L, significantly lower than 【(814.1±225.1)mg/L, P<0.05】,and serum IgA level was (509.1±128.6)mg/L, significantly lower than 【(749.7±231.9)mg/L, P<0.05】 in the control; during the treatment, the incidence of side effects in the combination group was 18.0%, not significantly different as compared to 4.9% in the control group (P>0.05). Conclusion The steroid free treatment, e.g. Liganlong, a herbal medicine, and magnesium isoglycyrrhizinate combination, in patients with autoimmune hepatitis is a real viable option to obtain remission, that might be related to the inhibition of humoral immunity, reduction of serum CF-8 , CF-9 and CF-2 levels and obviously improvement of liver functions.

Key words: Autoimmune hepatitis, Liganlong,herbal medicine, Magnesium isoglycyrrhizinate, Humoral immunity, Chemokine-8, Therapy

王雨, 王楠, 王巧侠, 马清华, 潘新杰, 付建军. 利肝隆联合异甘草酸镁治疗自身免疫性肝炎患者疗效及其对血清趋化因子水平的影响^*[J]. 实用肝脏病杂志, 2020, 23(6): 821-824.

Wang Yu, Wang Nan, Wang Qiaoxia, et al. Liganlong and magnesium isoglycyrrhizate combination mitigates liver injury via inhibiting humoral immunity in patients with autoimmune hepatitis[J]. Journal of Practical Hepatology, 2020, 23(6): 821-824.

参考文献

[1] 赵素贤, 张玉果, 谭普芳, 等.药物诱导的自身免疫性肝炎与药物性肝损伤的临床特征对照研究.中华肝脏病杂志, 2016, 24(4): 302-306.
[2] 张洪文, 刘会敏, 林睿, 等.自身免疫性肝炎治疗应答不良患者的临床特点分析.中华肝脏病杂志, 2017, 25(10): 755-759.
[3] Giuseppe M. Steroid free treatment in autoimmune hepatitis: is azathioprine monotherapy truly a viable option to obtain remission. J Pediatr, 2019, 210(8): 56-58.
[4] Gao MX, Li XL, He LL, et al. Diammonium glycyrrhizinate mitigates liver injury via inhibiting proliferation of NKT cells and promoting proliferation of Tregs. Drug Des Devel Ther, 2019, 13(7): 98-100.
[5] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015). 中华传染病杂志, 2016, 34(4): 193-208.
[6] 龙梅, 王丽旻, 朱莉, 等. 自身免疫性肝炎患者临床和肝组织病理学特征.实用肝脏病杂志, 2020, 23(1): 142-143.
[7] Peters MG. Long-term use of azathioprine in the management of autoimmune hepatitis.Nat Rev Gastroenterol Hepatol, 2019, 15(5): 53-56.
[8] Shi HJ,Song HB,Gao Q, et al. Combination of oxymatrine and diammonium glycyrrhizinate significantly mitigates mice allergic contact dermatitis induced by dinitrofluorobenzene. Exp Biol Med, 2019, 244(13): 78-81.
[9] Zeman MV, Hirschfield GM. Autoantibodies and liver disease: uses and abuses. Can J Gastroenterol, 2016, 24(4): 225-231.
[10] Anna P, Malgorzata SP, Malgorzata P. Evaluation of the effectiveness of treatment with prednisone and azathioprine of autoimmune hepatitis in children. Prz Gastroenterol, 2016, 11(1): 18-23.
[11] Kalinskabienias A, Jakubowska B, Kowalewski C, et al. Measuring of quality of life in autoimmune blistering disorders in Poland. validation of disease specific autoimmune bullous disease quality of life(abqol) and the treatment autoimmune bullous disease quality of life (tabqol) questionnaires. Adv Med Sci, 2017, 62(1): 92-96.
[12] Chaouali M, Fernandes V, Ghazouani E, et al. Association of stat4, TGFβ1, sh2b3 and ptpn22 polymorphisms with autoimmune hepatitis. Exp Mol Pathol, 2018, 105(3): 279-284.
[13] Rizvi S, Gawrieh S. Autoimmune hepatitis in the elderly: diagnosis and pharmacologic management. Drugs Aging, 2018, 35(7): 589-602.
[14] Yang Q, Wang J, Liu R, et al. Amelioration of concanavalin A induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of cd4(+)cd25(-)cd69(+)subset proliferation. Drug Des Devel Ther, 2016, 25(10): 443-53.
[15] Tan QY, Hu Q, Zhu SN, et al. Licorice root extract and magnesium isoglycyrrhizinate protect against triptolide-induced hepatotoxicity via up-regulation of the nrf2 pathway. Drug Deliv, 2018, 25(1): 1213-1223.
[16] Sun W, Wu HY, Chen S. Influence of tbx21 t-1993c varianton autoimmune hepatitis development by yin-yang 1 binding. World J Gastroenterol, 2017, 23(48): 8500-8511.
[17] Buechter M, Manka P, Heinemann FM, et al. Potential triggering factors of acute liver failure as a first manifestation of autoimmune hepatitis-a single center experience of 52 adult patients. World J Gastroenterol, 2018, 24(13): 1410-1418.
[18] 张攀, 刘涛, 王芳芹, 等. 异甘草酸镁对小鼠放射性肺纤维化的改善作用及其机制的初步研究. 中国药理学通报, 2017, 33(2): 201-206.
[19] Ma D, Zhang J, Zhang Y, et al. Inhibition o f myocardial hypertrophy by magnesium isoglycyrrhizinate through the tlr4/nf-kb signaling pathway in mice. Int Immunopharmacol, 2018, 55(8): 237-244.
[20] Zhai XF, Wang SL, Zhu MY, et al. Antiviral effect of lithium chloride and diammonium glycyrrhizinate on porcine deltacoronavirus in vitro. Pathogens, 2019, 8(3): 56-58.
[21] Sebode M, Hartl J, Vergani D, et al. Autoimmune hepatitis: from current knowledge and clinical practice to future research agenda. Liver Int, 2018, 38(1): 15-22.

利肝隆联合异甘草酸镁治疗自身免疫性肝炎患者疗效及其对血清趋化因子水平的影响^*

Liganlong and magnesium isoglycyrrhizate combination mitigates liver injury via inhibiting humoral immunity in patients with autoimmune hepatitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周新民, 丁小鹏. 基础肝病治疗在原发性肝癌综合治疗中的重要作用[J]. 实用肝脏病杂志, 2021, 24(1): 4-6.
[2]	刘奇, 郝吉庆. 免疫联合治疗肝细胞癌研究进展[J]. 实用肝脏病杂志, 2021, 24(1): 7-9.
[3]	郑志恒, 李维筠, 回振宇, 陈莹. 聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙型肝炎患者疗效及血清Pygo2和GP73水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 19-22.
[4]	林金祥, 杨可立. PEG-IFNα-2a与PEG-IFNα-2b治疗慢性乙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 27-30.
[5]	樊秉栋, 张国华, 王君. 索磷布韦/维帕他韦联合利巴韦林治疗慢性丙型肝炎患者疗效临床研究[J]. 实用肝脏病杂志, 2021, 24(1): 31-34.
[6]	杨晓冬, 贾婷, 张秀灵, 高斯媛, 余向琼, 李冬玲, 喻明丽, 林潮双. 达诺瑞韦联合长效α-干扰素治疗基因3型慢性丙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 35-38.
[7]	魏秀琴, 闫晓霞, 石国荣, 赵宏伟, 李基寿. 阿托伐他汀联合硫普罗宁治疗非酒精性脂肪性肝病患者疗效初步研究[J]. 实用肝脏病杂志, 2021, 24(1): 47-50.
[8]	李钊, 黄赞松, 李繁. 非诺贝特联合双环醇治疗非酒精性脂肪性肝病患者肝组织PPARγ₂mRNA水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 59-62.
[9]	陈金玉, 郭晓霞, 钟晓妮. 二甲双胍联合双歧杆菌三联活菌胶囊治疗非酒精性脂肪性肝病患者疗效及血清IRS1、IRS2和GLUT4的变化[J]. 实用肝脏病杂志, 2021, 24(1): 63-66.
[10]	陈燕屏, 黄绍强, 邓鑫, 熊超. 硫普罗宁联合多烯磷脂酰胆碱治疗酒精性肝病患者疗效及血清TLR4、MD-2和TGF-β1水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 67-70.
[11]	蔡宇, 王孟春, 邱新平, 张宁宁, 刘丽莉, 吴博, 杨奇. 复方甘草酸苷联合丁二磺酸腺苷蛋氨酸治疗酒精性肝炎伴胆汁淤积患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 71-74.
[12]	伍畅, 田园, 刘洪岩. 酪酸梭菌活菌辅助硫普罗宁和美他多辛治疗酒精性肝病患者疗效及其对患者肠道菌群分布的影响[J]. 实用肝脏病杂志, 2021, 24(1): 75-78.
[13]	李庆玲, 何树光, 易小明, 段婷娜, 周意. 雷公藤多甙联合异甘草酸镁治疗自身免疫性肝炎患者外周血淋巴细胞PD-1和PD-L1变化[J]. 实用肝脏病杂志, 2021, 24(1): 79-82.
[14]	曾娇, 郭贵海. 聚乙二醇与乳果糖治疗肝性脑病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2021, 24(1): 99-102.
[15]	范静, 徐静, 袁雪. 利福昔明联合乳果糖治疗肝性脑病患者疗效及其血清S100B蛋白和神经元特异性烯醇化酶变化[J]. 实用肝脏病杂志, 2021, 24(1): 103-106.